Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Texas AG goes after generics makers
It's not just branded drugmakers who are being targeted for Medicaid fraud. The Texas Attorney General is going after four generics makers for allegedly stating falsely inflated prices for their medications. Watson Pharmaceutcials, Alpharma, Par Pharmaceutical and Barr Pharmaceuticals listed artificially high prices all the way back to the 1990s, the AG claims. Medicaid then reimbursed pharmacies at those inflated prices, giving the pharmacies windfall profits--and "unlawfully" inducing them and other customers to buy more from the drugmakers.
The probe's roots lie in a whistleblower lawsuit that's under court seal. That suit has led to action against several drugmakers for similar pricing schemes, including Schering-Plough, Boehringer Ingelheim, and Baxter Healthcare.
- see the AG's press release
- read the Pharmalot item
Related Articles:
AL jury: GSK, Novartis will pay
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


